CLDX Celldex Therapeudics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLDX Celldex Therapeudics

CLDX 23.71

-0.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: Michael L	10/9/2016 7:45:07 AM
	of 105

Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response HAMPTON, N.J., Oct. 09, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ( CLDX) today presented positive results from the Company’s Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK inhibitor-refractory metastatic melanoma (n=62). Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate (ADC) that targets glycoprotein NMB (gpNMB), a protein overexpressed by multiple tumor types, including metastatic melanoma where greater than 80% of patients overexpress the marker. High tumor expression of gpNMB is associated with shorter metastasis-free survival and reduced overall survival.1 Study results were presented today at the ESMO 2016 Congress in Copenhagen in poster titled “ A Phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext